MASH

The AJMC^® metabolic dysfunction-associated steatohepatitis compendium is a comprehensive resource for clinical news and expert insights for the condition, which was formerly known as nonalcoholic steatohepatitis.

Latest News

February 6th 2025

MASH-Related PLC on the Rise in Young Adults

By Kyle Munz

January 28th 2025

"Alarming Rise" of Global MASH-Related Primary Liver Cancer Incidence Since 2000

By Kyle Munz

January 27th 2025

Amplifying Impact: Efruxifermin Plus GLP-1RA Elevates MASH Outcomes

By Kyle Munz

January 20th 2025

A Potential Early Biomarker for MASLD: Oxidized Apolipoproteins

By Kyle Munz

June 12th 2024

Study Highlights Increasing Global Health Burden of Liver Cancer

By Rose McNulty

More News

Blue FDA approved stamp | Imaged credit: Olivier Le Moal - stock.adobe.com

March 14th 2024

FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis

Laura Joszt, MA

The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.

October 11th 2022

ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments

Laura Joszt, MA

There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.

November 23rd 2021

Improving Early Detection of Nonalcoholic Steatohepatitis on Ultrasound

Rose McNulty

A recent study aims to improve evaluation of fatty liver in ultrasound scans to increase hepatology referrals and predict significant liver fibrosis.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions